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ABSTRACT
Background: Restless legs syndrome (RLS) is associated
with common variants in three intronic and intergenic
regions in MEIS1, BTBD9, and MAP2K5/LBXCOR1 on
chromosomes 2p, 6p and 15q.
Methods: Our study investigated these variants in 649
RLS patients and 1230 controls from the Czech Republic
(290 cases and 450 controls), Austria (269 cases and 611
controls) and Finland (90 cases and 169 controls). Ten
single nucleotide polymorphisms (SNPs) within the three
genomic regions were selected according to the results of
previous genome-wide scans. Samples were genotyped
using Sequenom platforms.
Results: We replicated associations for all loci in the
combined samples set (rs2300478 in MEIS1,
p = 1.2661025, odds ratio (OR) = 1.47, rs3923809 in
BTBD9, p = 4.1161025, OR = 1.58 and rs6494696 in
MAP2K5/LBXCOR1, p = 0.04764, OR = 1.27). Analysing
only familial cases against all controls, all three loci were
significantly associated. Using sporadic cases only, we
could confirm the association only with BTBD9.
Conclusion: Our study shows that variants in these three
loci confer consistent disease risks in patients of European
descent. Among the known loci, BTBD9 seems to be the
most consistent in its effect on RLS across populations
and is also most independent of familial clustering.
Restless legs syndrome (RLS) is characterised by an
urge to move the legs associated with unpleasant
sensations in the lower limbs, typically occurring
at rest in the evening or at night.1 Since the
maximum number of symptoms appear at bed-
time, RLS can lead to disturbances of sleep
resulting in a decreased quality of life.1 The
diagnosis is further supported by the presence of
periodic limb movements in sleep (PLMS) and
positive response to dopaminergic treatment.1
A recent genome-wide association study (GWA)
with German and Canadian RLS cases identified
intronic or intergenic variants within three genomic
regions: MEIS1 (myeloid ecotropic viral integration
site homeobox 1) on chromosome 2p, BTBD9 (BTB/
POZ domain containing protein 9) on chromosome
6p, and a third region on chromosome 15q containing
MAP2K5 (mitogen activated protein kinase kinase 5)
and LBXCOR1 (ladybird homeobox co-repressor 1).2 A
similar study conducted in Icelandic and US cases
showed an association of BTBD9 to PLMs.3
MEIS1 belongs to the family of TALE homeobox
genes involved in limb development, the determi-
nation of the megakaryocytes and central nervous
system (CNS) structures, such as the retina,
cerebellar granule cells, hindbrain and spinal motor
neuron pools.4–6 So far, very little is known about
BTBD9. It consists of a BTB/POZ domain, a BACK
domain and a coagulation factor domain. Known
functions of similar proteins containing these
domains include ubiquitin dependent protein
degradation.7 The variants located in the third
genetic region are in strong linkage disequilibrium
with two surrounding genes: MAP2K5, which is
critical at early stages of muscle cell differentia-
tion,8 and LBXCOR1, which is a transcriptional co-
repressor of LBX1 and is highly expressed in spinal
dorsal horn and midbrain–hindbrain border.9 The
involvement of these genes in the aetiopathogen-
esis of RLS is still unknown.
The aim of our study was to investigate whether
these variants are also relevant among other
European (Czech, Austrian, and Finnish) RLS cases
and what is the difference of their impact between
sporadic and familial cases.
PATIENTS AND METHODS
Patients and controls
The diagnosis of all RLS cases was made according
to diagnostic criteria of the International RLS
Study Group1 by personal examination by a
neurologist in the respective study centre. The
positive family history was defined as at least one
first degree family member being affected by RLS
(reported by the proband) in all three populations.
The control samples originate from the general
population and were not screened for presence of
RLS.
Czech subjects
The patients were recruited in the Centre for
Disorders of Sleep and Wakefulness, Department
of Neurology of First Faculty of Medicine and the
General Teaching Hospital, Prague. In total, 290
patients were included (107 males, mean (SD) age
55.7 (15.3) years, mean age at onset of RLS 38.3
(18.1) years). Positive family history was reported
by 110 patients, in 175 cases it was negative, and in
five the data were not available. Altogether 450 sex
matched controls were selected randomly from the
Czech blood and bone marrow donors registry (166
males, mean age 45.3 (9.9) years). Since the
maximum age for the controls was 63 years, 38
male and 51 female cases in the age group from 64
to 91 years could not be age matched.
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Austrian subjects
A total of 269 (104 males) patients were recruited in 2 centres:
at the Department of Neurology, Medical University of Vienna,
and the Department of Neurology, University Clinic Innsbruck,
(mean age 59.0 (14.3) years, mean age at onset of RLS 37.14
(19.5) years). Positive family history was reported by 107
patients, in 108 cases it was negative, and in 54 the data were
not available. The patients were matched by sex to 611 controls
from the German KORA project, the procedures for which have
been described elsewhere10 (236 males, mean age 59.9
(11.35) years). KORA controls were already used in the previous
GWA study, which showed only a negligible effect of
population stratification.2
Finnish subjects
Ninety (24 males) patients were recruited in the Sleep Research
Center in Turku (mean age 46.5 (18.1) years, mean age at onset
of RLS 19.4 (13.4) years. Positive family history was reported by
81 patients and nine patients had a negative family history. A
random sample from the general Finnish population, comprising
169 sex matched individuals (45 males), was used as control.
Data on age of controls were not available. Studies were
performed according to the declaration of Helsinki and
approved by the ethical committees of the respective study
centres. Written informed consent was obtained from all RLS
patients.
Genotyping
Ten single nucleotide polymorphisms (SNPs) within the three
genomic regions were selected according to the results of
previous GWA scans.2 3 Samples were genotyped on two
Sequenom platforms in Munich and Helsinki (Sequenom
MassArray system, Sequenom Inc, San Diego, California,
USA) with a genotype discordance rate of 1.3% in 158
comparisons, when analysing repeatedly genotyped internal
control samples. Automated genotype calling was done with
SpectroTYPER 3.4 software and genotype clustering was
visually checked by an experienced scientist. Assays were
designed using AssayDesign 3.1.2.2 with iPLEX Gold chemistry
default parameters. SNP quality control criteria leading to
exclusion from analysis were a call rate ,90%, minor allele
frequencies (MAF) ,1% and p,0.001 for deviations from
Hardy-Weinberg equilibrium (HWE) in controls.
Statistical analysis
Genotype data were analysed using standard association tests
(allelic, genotypic, dominant and recessive models) including
Cochran–Armitage test for trend, Cochran–Mantel–Haenszel
test for estimation of odds ratios (ORs) in the stratified sample
(including Breslow–Day test for homogeneity), and haplotype
tests, as implemented in the PLINK statistical package v1.0.11
The sample was stratified only according to the country of
origin. Logistic regression implementing the Cochran–Armitage
test for trend (using genotypes as ordinal values rather than
categorical) in the combined sample using age, sex and
country of origin as covariates was performed by generalised
linear modelling routines incorporated in R package v.2.6.0
(http://www.r-project.org/). Bonferroni correction for multiple
testing of 10 markers was employed. All p values given are one
sided, with the direction of the alternative hypothesis given by the
original report.3 Power calculations were performed using the
Genetic Power Calculator (pngu.mgh.harvard.edu/,purcell/gpc/).12
For input parameter we used an RLS prevalence of 8%, an a
level of 5%, and ORs and allele frequencies according to
results from the GWA experiment.2 Association tests were
conducted in three different settings: (1) all patients (that is,
familial and sporadic) combined versus all controls; (2)
familial cases versus controls; and (3) sporadic cases versus
controls.
RESULTS
All SNPs tested were in HWE (p.0.01) in both patients and
controls. Under the assumption of genetic homogeneity, the
combined sample had good power to detect association using
previously published parameters2 (98% for MEIS1 and BTBD9,
89% for MAP2K5/LBXCOR1). In the Czech sample alone the
power was 82.5% for MEIS1 and BTBD9, and 71.8% for
MAP2K5/LBXCOR1, in the Austrian sample the powers were
84.8% and 74.8%, respectively, and in the Finnish sample
separately 38.7% and 30.4%.
Allele frequencies in the Czech and KORA control samples
were not significantly different (lowest p in x2 test = 0.2045 for
rs4236060). Significant allele frequency differences were
observed between the Finnish and the combined Czech and
KORA control samples within BTBD9 (p,7.6761026 for all SNP
markers within BTBD9). A similar, nominally significant,
difference in allele frequencies in BTBD9 markers was also
observed between Finnish cases and combined Czech and
Austrian cases (in x2 test lowest p = 0.01063 for rs9296249),
but we did not observe a significant difference between allele
frequencies of Czech and Austrian RLS patients (lowest p in x2
test was 0.4608 for rs2300478). Logistic regression showed no
significant interaction with country for any SNP tested, and the
Breslow–Day test showed homogeneous ORs in all samples.
Significant association after correction for multiple testing at
significance a level of 5% was found in at least one SNP for all
tested loci in the combined samples (table 1), and in the Czech
and Austrian samples separately. Analysing the Finnish sample,
we confirmed only the association to BTBD9. The association to
rs2300478 in MEIS1 was only nominally significant and
MAP2K5/LBXCOR1 showed no association (table 2).
In the combined sample we observed a strong association
with the haplotype formed by markers rs6710341 and
rs12469063, both located within MEIS1. Carriers of the ‘‘AG’’
haplotype had ORs for developing RLS of 1.98 (p = 9.1610210).
Results for this haplotype were similar when testing the Czech
(p = 3.2 1027, OR = 2.38), Austrian (p = 8.361025, OR = 1.82),
and Finnish samples (p = 2.061024, OR = 2.46) separately. No
other common polymorphic phased haplotypes (MHF .1%)
yielded significant results. An allele dosage model best described
the association for MEIS1 and BTBD9 (Armitage trend test). In
contrast, a recessive model for the risk allele fitted best for the
MAP2K5/LBXCOR1 locus.
Analysing only familial cases (n = 217) and all controls, all
three loci were significantly associated. Using sporadic cases
only (n = 283), we could confirm the association to BTBD9 but
not to MEIS1 and MAP2K5/LBXCOR1. We omitted patients of
Finnish origin from this sub-analysis due to very low proportion
of sporadic cases and different allele frequencies in these
samples. The Breslow–Day test did not show significant
heterogeneity between sporadic and familial cases.
DISCUSSION
Our study showed an association of variants in MEIS1, BTBD9
and MAP2K5/LBXCOR1 with RLS in a combined sample of
Czech, Austrian, and Finnish RLS cases. Similar findings were
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observed in the US population.13 In accordance with the original
report, the strongest effect was observed with the haplotype
‘‘AG’’ formed by markers rs6710341 and rs12469063 located in
the ninth intron of MEIS1, providing ORs of about 2.0 for this
haplotype. However, the OR may be underestimated, because
the controls samples were not screened to exclude RLS and
therefore may contain approximately 10% of individuals
actually affected by RLS. The best models observed for
individual loci are in good agreement with previous findings
in German and Canadian populations. The significance of these
loci to RLS can therefore be regarded as well established.
The sub-analyses in Czech and Austrian populations show
the same trends for association as the combined sample, but in
the Finnish sample, only association with BTBD9 was confirmed
and there was a trend for association to MEIS1. Moreover, the
allele frequencies and proportions of familial cases in the Finnish
sample were different from the other two, but the smaller size
of this sample limits further implications.
In our sample set we have not observed significant differences
between familial and sporadic cases concerning the BTBD9
locus. The 95% confidence intervals of OR also overlapped
between familial and sporadic cases for both MEIS1 (1.357 to
2.1 in familial and 1.019 to 1.534 in sporadic cases vs all controls
for rs12469063) and MAP2K5/LBXCOR1 (1.164 to 1.841 in
familial and 0.951 to 1.408 in sporadic cases for rs6494696).
There is a trend that MEIS1 and MAP2K5/LBXCOR1 possibly
play a more important role in familial RLS, but due to the
limited number of patients, we were not able to prove
significant heterogeneity. Generally the risk alleles in these loci
are common and exert only small to moderate effects. They do
not explain the familial clustering of RLS.2 Besides these
association signals, six linkage regions for RLS on chromosomes
2q, 9p, 12q, 14q, 19p and 20p,14–19 under a recessive or autosomal
dominant model of inheritance, have been described. These
variants must be of larger effects and less frequent, since only
some have been successfully confirmed in independent popula-
tions or in single families.20–24 Among the known loci, BTBD9
seems to be the most consistent in its effect on RLS across
populations, and is also most independent of familial clustering.
We conclude that the observed genetic determinants are risk
factors for RLS in multiple populations.
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